Searching. Please wait…
1582
37
170
29108
4409
2600
347
389
Abstract: In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based on current evidence. As this field is constantly evolving, these guidelines have been updated, previously in 2012 and 2015 and now in 2019. Current evidence suggests that the mandatory tests to conduct in all patients with advanced NSCLC are for EGFR and BRAF mutations, ALK and ROS1 rearrangements and PD-L1 expression. The growing need to study other emerging biomarkers has promoted the routine use of massive sequencing (next-generation sequencing, NGS). The coordination of every professional involved and the prioritisation of the most suitable tests and technologies for each case remains a challenge.
Fuente: Clinical and Translational Oncology, 2020, 22(7), 989-1003
Publisher: Springer-Verlag Italia
Year of publication: 2020
No. of pages: 15
Publication type: Article
DOI: 10.1007/s12094-019-02218-4
ISSN: 1699-048X,1699-3055
Publication Url: https://www.doi.org/10.1007/s12094-019-02218-4
Consult in UCrea Read publication
GARRIDO, P.
CONDE, E.
CASTRO, J. DE
JOSE JAVIER GOMEZ ROMAN
FELIP, E.
PIJUAN, L.
ISLA, D.
SANZ, J.
PAZ ARES, L.
LÓPEZ RÍOS, F.
Back